HEALTH
Biotechnology Firm Gets Investment: Canji Inc., a privately held San Diego company, said it has reached a key research agreement with Schering-Plough Corp., a Madison, N.J., pharmaceutical firm. Schering-Plough is to provide financing to Canji, which is developing cancer treatments that use gene therapy technology, in exchange for worldwide marketing rights to products that use Canji’s p53 treatment. Schering-Plough did not disclose its initial investment, but it said the agreement could exceed $50 million if Canji reaches certain research milestones.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
